Results 191 to 200 of about 316,204 (367)

…and AHA announces support for the technique [PDF]

, 2000
Potter Wickware
openalex   +1 more source

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Andrea Lage, Katja Rohwedder, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +18 more
wiley   +1 more source

Optimization of renin‐angiotensin‐aldosterone inhibitor therapies for evidence‐based indications: a call to action from the cardio‐kidney community

ESC Heart Failure, EarlyView.
Roberto Pecoits‐Filho, Michelle M.Y. Wong, Monica Moorthy, Debasish Banerjee, Suman Behera, Viviane Calice‐Silva, Mogamat‐Yazied Chothia, Gates B. Colbert, Martha Gulati, Charles A. Herzog, Fadi Jouhra, Edgar V. Lerma, Charu Malik, Kershaw V. Patel, Amina Rakisheva, Giuseppe M.C. Rosano, Priyanka Satish, Henry H.L. Wu, Angela Yee‐Moon Wang   +18 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt, Pardeep S. Jhund, Alasdair D. Henderson, Brian L. Claggett, Akshay S. Desai, Carolyn S.P. Lam, Katharina Mueller, Markus F. Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray   +16 more
wiley   +1 more source

AVA in talks with AHA over APAV concerns [PDF]

, 2000

openalex   +1 more source

Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the CardioMEMS Heart Failure System

European Journal of Heart Failure, EarlyView.
Meta‐analysis on the main outcomes of pulmonary artery pressure (PAP)‐guided management with the CardioMEMS Heart Failure (HF) System in patients with HF outside clinical trials. Effect measures are expressed as pooled means (95% CI), mean differences (95% CI), or pooled incidence rate ratios (95% CI), as appropriate.
Chris J. Kapelios, Sotiria Liori, Michael Bonios, William T. Abraham, Gerasimos Filippatos   +4 more
wiley   +1 more source

Comparison of the application of treatment Panel III and American College of Cardiology/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia

Journal of the Saudi Heart Association, 2018
Background: One of the major risk factors for cardiovascular diseases is hyperlipidemia. The primary aim of this study was to estimate the proportion of individuals between 40–75 years old that would be eligible for statin therapy based on ACC/AHA ...
Salahdein Aburuz, Abdulkareem Al-Bekairy, Abdul-Aziz Alqahtani, Khalid Harbi, Mohammed Al Nuhait, Abdullah Khoja, Adel Sadeq, Mohammed Al Rashed   +7 more
doaj  

Intervention to improve adherence to ACC/AHA recommended adjunctive medications for the management of patients with an acute myocardial infarction [PDF]

, 2001
Sandra S. Axtell, Elizabeth Ludwig, A. Lopez‐Candales   +2 more
openalex   +1 more source

The phenomenology of Aha-experiences. [PDF]

Motivation Science, 2020
Øystein O. Skaar, Rolf Reber
openaire   +2 more sources

Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
Abstract Aims N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non‐steroidal mineralocorticoid receptor antagonist finerenone on NT‐proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF)
Jonathan W. Cunningham, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Katja Rohwedder, Laura Goea, Mario Berger, John J.V. McMurray, Scott D. Solomon   +17 more
wiley   +1 more source